Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

AstraZeneca Recalls Single Lot of Nexium (esomeprazole magnesium) Delayed-Release Capsules
AstraZeneca has recalled a single lot of Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg. Lot number H008328 has been recalled because this lot may contain both Nexium 20 mg capsules and 40 mg capsules. Nexium contains the active ingredient esomeprazole magnesium and is commonly used in the treatment of heartburn. This recall alert only applies to the single lot of Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg. No other esomeprazole products were involved in this recall. To view the FDA notice about this recall, please visit: http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Event-Detail.cfm?action=detail&id=62439&w=07182012&
Learn More

Postmenopausal Hormone Therapy May Be Associated with Heartburn
A recent study published in the Archives of Internal Medicine suggests that postmenopausal women who use estrogens, such as ESTRADIOL, may have an increased risk of heartburn compared with postmenopausal women not taking these medications. For more information please visit: http://archinte.ama-assn.org/cgi/content/abstract/168/16/1798
Learn More

Date Published Title Drug Source
2012-07-25 AstraZeneca Recalls Single Lot of Nexium (esomeprazole magnesium) Delayed-Release Capsules Esomeprazole FDA
2008-11-10 Postmenopausal Hormone Therapy May Be Associated with Heartburn Estradiol MediGuard CRT
2009-03-09 Risk of Burns during MRI Scans from Transdermal Drug Patches with Metallic Backings Estradiol FDA
2009-06-08 Update on the Risk of Breast Cancer with Hormone Replacement Therapy Estradiol MediGuard CRT
2010-07-29 The FDA Announces Ongoing Safety Review of Evamist and Reports of Unintended Exposure of Children and Pets Estradiol FDA
2009-03-09 Risk of Burns during MRI Scans from Transdermal Drug Patches with Metallic Backings Estradiol and Norethindrone FDA
2008-08-15 Hormone replacement therapy (HRT) increases risk for non-cancerous breast disease and stroke Estrogen with Testosterone MediGuard CRT
2008-07-03 New Consumer Guide for Patients Estrogens Conjugated MediGuard CRT
2008-08-13 Hormone replacement therapy (HRT) increases risk for non-cancerous breast disease and stroke Estrogens Conjugated MediGuard CRT
2008-11-10 Postmenopausal Hormone Therapy May Be Associated with Heartburn Estrogens Conjugated MediGuard CRT
2009-06-08 Update on the Risk of Breast Cancer with Hormone Replacement Therapy Estrogens Conjugated MediGuard CRT
2013-01-03 Physicians Total Care Recalls Several Lots of Enjuvia Tablets Estrogens Conjugated FDA
2008-07-03 New Consumer Guide for Patients Estrogens Conjugated with Medroxyprogesterone MediGuard CRT
2008-08-13 Hormone replacement therapy (HRT) increases risk for non-cancerous breast disease and stroke Estrogens Conjugated with Medroxyprogesterone MediGuard CRT
2008-11-06 Recall of Single Lot of PREMPRO 0.3 mg/1.5 mg EZ-DIAL Dispensers Estrogens Conjugated with Medroxyprogesterone FDA
2008-11-14 Recall of Additional Lot of PREMPRO 0.3 mg/1.5 mg EZ-DIAL Dispensers Estrogens Conjugated with Medroxyprogesterone FDA
2009-06-08 Update on the Risk of Breast Cancer with Hormone Replacement Therapy Estrogens Conjugated with Medroxyprogesterone MediGuard CRT
2009-12-18 Recall of Several Lots of PREMPRO 0.3 mg/1.5 mg EZ-DIAL Dispensers Estrogens Conjugated with Medroxyprogesterone FDA
2010-02-19 Recall of Two Lots of PREMPRO 0.3 mg/1.5 mg EZ-DIAL Dispensers Estrogens Conjugated with Medroxyprogesterone FDA
2010-10-21 Hormone Replacement Therapy After Menopause Associated with Higher Risk of Aggressive Form of Breast Cancer Estrogens Conjugated with Medroxyprogesterone MediGuard CRT
Back to Consumer Med Safety